Search The Medical Knowledge Base

Drug Details

Marevan 0.5mg Tablets

• Drug Class Description
  synthetic anticoagulant
• Presentation
  White, flat, circular, bevel-edged uncoated tablets having 'M' breakline '0.5' on one side and plain on other side.
• Description
  Each tablet contains 0.5mg Warfarin Sodium Ph.Eur.
• Indications
  

  Prophylaxis of systemic embolism in patients with rheumatic heart disease and atrial fibrillation.

  Prophylaxis after insertion of prosthetic heart valves.

  Prophylaxis and treatment of venous thrombosis and pulmonary embolism.

  Transient attacks of cerebral ischaemia.

• Adult Dosage
  

  Adults: The typical induction dose is 10mg daily for 2 days but this should be tailored to individual requirements. The daily maintenance dose is usually 3 to 9mg taken at the same time each day. The exact maintenance dose depends on the prothrombin time or other appropriate coagulation tests.

  Control tests should be made at regular intervals and the maintenance dose should be adjusted according to the results obtained. Once the maintenance dose is established, it is rarely necessary to alter it.

  In emergencies, anticoagulant therapy should be initiated with heparin and warfarin together.

  Concomitant therapy with heparin affects the results of control tests, and should be discontinued at least six hours before the first test is carried out.

  Elderly: As for adults, but dosage may need to be lowered.

  Children: Dosage for children has not been established.

  Method of administration: Oral.

• Child Dosage
  

  Dosage for children has not been established.

• Elderly Dosage
  

   As for adults, but dosage may need to be lowered.

• Contra Indications
  

  • Known hypersensitivity to warfarin or to any of the excipients

  • Haemorrhagic stroke

  • Clinically significant bleeding

  • Within 72 hours of major surgery with risk of severe bleeding

  • Within 48 hours postpartum

  • Pregnancy

  • Drugs where interactions may lead to a significantly increased risk of bleeding

• Special Precautions
  

  Most adverse events reported with warfarin are a result of over anticoagulation therefore it is important that the need for therapy is reviewed on a regular basis and therapy discontinued when no longer required.

  Patients should be given a patient-held information booklet ('warfarin card') and informed of symptoms for which they should seek medical attention.

  Commencement of therapy

  Monitoring

  When warfarin is started using a standard dosing regimen the INR should be determined daily or on alternate days in the early days of treatment. Once the INR has stabilised in the target range the INR can be determined at longer intervals.

  INR should be monitored more frequently in patients at an increased risk of over coagulation e.g. patients with severe hypertension, liver or renal disease.

  Patients for whom adherence may be difficult should be monitored more frequently.

  Thrombophilia

  Patients with protein C deficiency are at risk of developing skin necrosis when starting warfarin treatment. In patients with protein C deficiency, therapy should be introduced without a loading dose of warfarin even if heparin is given. Patients with protein S deficiency may also be at risk and it is advisable to introduce warfarin therapy slowly in these circumstances.

  Risk of haemorrhage

  The most frequently reported adverse effect of all oral anticoagulants is haemorrhage. Warfarin should be given with caution to patients where there is a risk of serious haemorrhage (e.g. concomitant NSAID use, recent ischaemic stroke, bacterial endocarditis, previous gastrointestinal bleeding).

  Risk factors for bleeding include high intensity of anticoagulation (INR>4.0), age 65, highly variable INRs, history of gastrointestinal bleeding, uncontrolled hypertension, cerebrovascular disease, serious heart disease, risk of falling, anaemia, malignancy, trauma, renal insufficiency, concomitant drugs. All patients treated with warfarin should have INR monitored regularly. Those at high risk of bleeding may benefit from more frequent INR monitoring, careful dose adjustment to desired INR, and a shorter duration of therapy. Patients should be instructed on measures to minimise risk of bleeding and to report immediately to physicians signs and symptoms of bleeding.

  Checking the INR and reducing or omitting doses depending on INR level is essential, following consultation with anticoagulation services if necessary. If the INR is found to be too high, reduce dose or stop warfarin treatment; sometimes it will be necessary to reverse anticoagulation. INR should be checked within 2–3 days to ensure that it is falling.

  Any concomitant anti-platelet drugs should be used with caution due to an increased risk of bleeding.

  Haemorrhage

  Haemorrhage can indicate an overdose of warfarin has been taken.

  Unexpected bleeding at therapeutic levels should always be investigated and INR monitored.

  Ischaemic stroke

  Anticoagulation following an ischaemic stroke increases the risk of secondary haemorrhage into the infarcted brain. In patients with atrial fibrillation long term treatment with warfarin is beneficial, but the risk of early recurrent embolism is low and therefore a break in treatment after ischaemic stroke is justified. Warfarin treatment should be re-started 2–14 days following ischaemic stroke, depending on the size of the infarct and blood pressure. In patients with large embolic strokes, or uncontrolled hypertension, warfarin treatment should be stopped for 14 days.

  Surgery

  For surgery where there is no risk of severe bleeding, surgery can be performed with an INR of <2.5.

  For surgery where there is a risk of severe bleeding, warfarin should be stopped 3 days prior to surgery.

  Where it is necessary to continue anticoagulation e.g. risk of life-threatening thromboembolism, the INR should be reduced to <2.5 and heparin therapy should be started.

  If surgery is required and warfarin cannot be stopped 3 days beforehand, anticoagulation should be reversed with low-dose vitamin K.

  The timing for re-instating warfarin therapy depends on the risk of post-operative haemorrhage. In most instances warfarin treatment can be re-started as soon as the patient has an oral intake.

  Dental Surgery

  Warfarin need not be stopped before routine dental surgery, eg, tooth extraction.

  Active peptic ulceration

  Due to a high risk of bleeding, patients with active peptic ulcers should be treated with caution. Such patients should be reviewed regularly and informed of how to recognise bleeding and what to do in the event of bleeding occurring.

  Interactions

  Many drugs and foods interact with warfarin and affect the prothrombin time. Any change to medication, including self-medication with OTC products, warrants increased monitoring of the INR. Patients should be instructed to inform their doctor before they start to take any additional medications including over the counter medicines, herbal remedies or vitamin preparations.

  Thyroid disorders

  The rate of warfarin metabolism depends on thyroid status. Therefore patients with hyper- or hypo-thyroidism should be closely monitored on starting warfarin therapy.

  Additional circumstances where changes in dose may be required

  The following also may exaggerate the effect of warfarin tablets, and necessitate a reduction of dosage:

  • Loss of weight

  • Acute illness

  • Cessation of smoking

  The following may reduce the effect of warfarin tablets, and require the dosage to be increased:

  • Weight gain

  • Diarrhoea

  • Vomiting

  Other warnings

  Acquired or inherited warfarin resistance should be suspected if larger than usual daily doses of warfarin are required to achieve the desired anticoagulant effect.

  Genetic information

  Genetic variability particularly in relation to CYP2C9 and VKORC1 can significantly affect dose requirements for warfarin. If a family association with these polymorphisms is known extra care is warranted.

• Interactions
  

  Warfarin has a narrow therapeutic range and care is required with all concomitant therapy. The individual product information for any new concomitant therapy should be consulted for specific guidance on warfarin dose adjustment and therapeutic monitoring. If no information is provided the possibility of an interaction should be considered. Increased monitoring should be considered when commencing any new therapy if there is any doubt as to the extent of interaction.

  Pharmacodynamic interactions

  Drugs which are contraindicated

  Concomitant use of drugs used in the treatment or prophylaxis of thrombosis, or other drugs with adverse effects on haemostasis may increase the pharmacological effect of warfarin, increasing the risk of bleeding.

  Fibrinolytic drugs such as streptokinase and alteplase are contraindicated in patients receiving warfarin.

  Drugs which should be avoided if possible

  The following examples should be avoided, or administered with caution with increased clinical and laboratory monitoring:

  • Clopidogrel

  • NSAIDs (including aspirin and cox-2 specific NSAIDS)

  • Sulfinpyrazone

  • Thrombin inhibitors such as bivalirudin, dabigatran

  • Dipyridamole

  • Unfractionated heparins and heparin derivatives, low molecular weight heparins

  • Fondaparinux, rivaroxaban

  • Glycoprotein IIb/IIIa receptor antagonists such as eptifibatide, tirofiban and abciximab

  • Prostacyclin

  • SSRI and SNRI antidepressants

  • Other drugs which inhibit haemostasis, clotting or platelet action

  Low-dose aspirin with warfarin may have a role in some patients but the risk of gastrointestinal bleeding is increased. Warfarin may initially be given with a heparin in the initial treatment of thrombosis, until the INR is in the correct range.

  Metabolic interactions

  Warfarin is a mixture of enantiomers which are metabolised by different CYPP450 cytochromes. R-warfarin is metabolised primarily by CYP1A2 and CYP3A4. S-warfarin is metabolised primarily by CYP2C9. The efficacy of warfarin is affected primarily when the metabolism of S-warfarin is altered.

  Drugs that compete as substrates for these cytochromes or inhibit their activity may increase warfarin plasma concentrations and INR, potentially increasing the risk of bleeding. When these drugs are co-administered, warfarin dosage may need to be reduced and the level of monitoring increased.

  Conversely, drugs which induce these metabolic pathways may decrease warfarin plasma concentrations and INR, potentially leading to reduced efficacy. When these drugs are co-administered, warfarin dosage may need to be increased and the level of monitoring increased.

  There is a small subset of drugs for which interactions are known; however the clinical effect on the INR is variable, in these cases increased monitoring on starting and stopping therapy is advised.

  Care should also be taken when stopping or reducing the dose of a metabolic inhibitor or inducer, once patients are stable on this combination (offset effect).

  Listed below are drugs which are known to interact with warfarin in a clinically significant way.

  Examples of drugs which potentiate the effect of warfarin

  allopurinol, capecitabine, erlotinib, disulfiram, azole antifungals (ketoconazole, fluconazole etc)

  omeprazole, paracetamol (prolonged regular use), propafenone, amiodarone, tamoxifen, methylphenidate

  zafirlukast, fibrates, statins (not pravastatin; predominantly associated with fluvastatin)

  erythromycin, sulfamethoxazole, metronidazole

  Examples of drugs which antagonise the effect of warfarin

  Barbiturates, primidone, carbamazepine, griseofulvin, oral contraceptives, rifampicin, azathioprine, phenytoin

  Examples of drugs with variable effect

  Corticosteroids, nevirapine, ritonavir

  Other drug interactions

  Broad spectrum antibiotics may potentiate the effect of warfarin by reducing the gut flora which produce vitamin K. Similarly, orlistat may reduce absorption of vitamin K. Cholestyamine and sucralfate potentially decrease absorption of warfarin.

  Increased INR has been reported in patients taking glucosamine and warfarin. This combination is not recommended.

  Interactions with herbal products

  Herbal preparations containing St John's Wort (Hypericum perforatum) must not be used whilst taking warfarin due to a proven risk of decreased plasma concentrations and reduced clinical effects of warfarin.

  Many other herbal products have a theoretical effect on warfarin; however most of these interactions are not proven. Patients should generally avoid taking any herbal medicines or food supplements whilst taking warfarin, and should be told to advise their doctor if they are taking any, as more frequent monitoring is advisable.

  Alcohol

  Acute ingestion of a large amount of alcohol may inhibit the metabolism of warfarin and increase INR. Conversely, chronic heavy alcohol intake may induce the metabolism of warfarin. Moderate alcohol intake can be permitted.

  Interactions with food and food supplements

  Individual case reports suggest a possible interaction between warfarin and cranberry juice, in most cases leading to an increase in INR or bleeding event. Patients should be advised to avoid cranberry products. Increased supervision and INR monitoring should be considered for any patient taking warfarin and regular cranberry juice.

  Limited evidence suggests that grapefruit juice may cause a modest rise in INR in some patients taking warfarin.

  Certain foods such as liver, broccoli, Brussels sprouts and green leafy vegetables contain large amounts of vitamin K. Sudden changes in diet can potentially affect control of anticoagulation. Patients should be informed of the need to seek medical advice before undertaking any major changes in diet.

  Many other food supplements have a theoretical effect on warfarin; however most of these interactions are not proven. Patients should generally avoid taking any food supplements whilst taking warfarin, and should be told to advise their doctor if they are taking any, as more frequent monitoring is advisable.

  Laboratory tests

  Heparins and danaparoid may prolong the prothrombin time, therefore a sufficient time interval should be allowed after administration before performing the test.

• Adverse Drug Reactions
  

  MedDRA system organ class	Adverse Reaction
  Infections and infestations	Fever
  Immune system disorders	Hypersensitivity
  Nervous system disorders	Cerebral haemorrhage; Cerebral subdural haematoma
  Vascular disorders	Haemorrhage
  Respiratory, thoracic and mediastinal disorders	Haemothorax, epistaxis
  Gastrointestinal disorders	Gastroinestinal haemorrhage, rectal haemorrhage, haematemesis; pancreatitis; diarrhoea; nausea; vomiting; melaena
  Hepatobiliary disorders	Jaundice; hepatic dysfunction
  Skin and subcutaneous disorders	Rash; alopecia; purpura; 'purple toes' syndrome; erythematous swollen skin patches leading to ecchymosis, infarction and skin necrosis
  Renal and Urinary disorders	Haematuria
  Investigations	Unexplained drop in haematocrit; haemoglobin decreased